Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

323
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
323
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous Glucose Monitoring for Detecting Hypoglycemia During Maintenance Therapy for Acute Lymphoblastic Leukemia.

Pediatrics international : official journal of the Japan Pediatric Society·2026
Same author

mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac).

Molecular therapy. Oncology·2026
Same author

Relevance of anti-Ku antibodies in Ku-positive myositis with a necrotizing myopathy-like phenotype: a pediatric case report.

Neuromuscular disorders : NMD·2026
Same author

Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.

British journal of haematology·2026
Same author

Concurrent central nervous system infection with Candida and Mycobacterium intracellulare in CARD9 deficiency: immunological insights from a single case.

Clinical and experimental immunology·2026
Same author

Bispecific Ligand-Based EphB4 CAR-T Cells Generated Using Ephrin-B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma.

Cancer science·2026

Related Experiment Video

Updated: Jun 22, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

CAR-T cell therapy in AML: recent progress and future perspectives.

Shoji Saito1,2, Yozo Nakazawa3,4

  • 1Department of Pediatrics, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, Nagano, 390-8621, Japan. shojis@shinshu-u.ac.jp.

International Journal of Hematology
|July 4, 2024
PubMed
Summary

Chimeric antigen receptor (CAR)-T cell therapy shows promise for acute myeloid leukemia (AML), but challenges like target heterogeneity and tumor microenvironment hinder development. Research continues for effective AML CAR-T cell therapies.

Keywords:
AMLCD123CLL-1Chimeric antigen receptorClinical trials

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

484
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

Related Experiment Videos

Last Updated: Jun 22, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

484
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Hematopoietic stem cell transplantation is the only curative option for many acute myeloid leukemia (AML) patients.
  • Chimeric antigen receptor (CAR)-T cell therapy is a promising next-generation treatment for hematological malignancies, including AML.

Purpose of the Study:

  • To review the challenges and prospects of developing CAR-T cell therapy specifically for acute myeloid leukemia (AML).
  • To discuss target antigen characteristics and on-target/off-tumor toxicities in AML CAR-T cell therapy.

Main Methods:

  • Review of current literature on CAR-T cell therapy for AML.
  • Analysis of various target antigens (CD33, NKG2D, CD123, CLL-1, CD7) and their expression patterns.
  • Discussion of clinical trial data and ongoing research.

Main Results:

  • AML CAR-T cell therapy development faces challenges including target antigen heterogeneity, on-/off-target effects, and an immunosuppressive tumor microenvironment.
  • Clinical trials targeting CLL-1 or CD123 have shown promising results, though no CAR-T products are yet widely practical.
  • Development of off-the-shelf CAR-T products is crucial due to difficulties in collecting autologous cells from AML patients.

Conclusions:

  • Despite challenges, CAR-T cell therapy holds significant potential for treating AML.
  • Continued research into ideal targets and overcoming toxicity is essential for clinical advancement.
  • Off-the-shelf CAR-T cell products represent a key area for future development in AML treatment.